ORLANDO, Fla.--(BUSINESS WIRE)--Dr. Theodore Chow today will present the results of the MASTER trial sponsored by Medtronic, Inc. The MASTER trial analyzed the results from 575 patients with left ventricular ejection fraction less than or equal to 30%. All of the patients underwent Microvolt T-Wave Alternans (MTWA) testing with Cambridge Heart’s HearTwave II system, and all received an implantable cardioverter defibrillator (ICD). At a press conference this morning, Dr. Chow presented the top-line results: while the ICD discharge rate, the primary endpoint, was lower in the MTWA negative group than in the non-negative group, this difference did not achieve statistical significance. However, MTWA was found to be predictive of total mortality (total mortality was 13% in the MTWA non-negative group and 6% in the MTWA negative group, hazard ratio = 2.04, p = 0.02).
